Japan Trade Groups Hail Progress in Reward for Innovation, but Fret Cost Disclosure Plans: FY2022 Reform

After a key reimbursement policy panel hammered out an outline of the FY2022 drug pricing reform , Japanese pharma industry groups issued statements on December 22 welcoming some progress made in the area of rewards for innovation, while raising concerns...read more